Trial record 1 of 1 for: 05564377

Previous Study | Return to List | Next Study

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05564377

Recruitment Status : Recruiting

First Posted : October 3, 2022

Last Update Posted : May 9, 2024

See Contacts and Locations

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

National Cancer Institute (NCI)

Study Description

Brief Summary:

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Condition or disease	Intervention/treatment	Phase
Advanced Malignant Solid Neoplasm Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Locally Advanced Malignant Solid Neoplasm Malignant Female Reproductive System Neoplasm Metastatic HER2-Negative Breast Carcinoma Metastatic Malignant Solid Neoplasm Recurrent Endometrial Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Malignant Female Reproductive System Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Unresectable HER2-Negative Breast Carcinoma Unresectable Malignant Solid Neoplasm	Drug: Alpelisib Drug: Binimetinib Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Scan Procedure: Computed Tomography Procedure: Echocardiography Drug: Fluorouracil Drug: Fulvestrant Drug: Ipatasertib Drug: Leucovorin Procedure: Magnetic Resonance Imaging Procedure: Multigated Acquisition Scan Procedure: Mutation Carrier Screening Drug: Neratinib Maleate Drug: Nilotinib Hydrochloride Monohydrate Drug: Olaparib Drug: Oxaliplatin Drug: Paclitaxel Drug: Palbociclib Biological: Panitumumab Procedure: Positron Emission Tomography Drug: Selumetinib Sulfate Drug: Sotorasib	Phase 2

Show detailed description

Detailed Description:

PRIMARY OBJECTIVE:

I. To register, allocate, and assign patients to ComboMATCH treatment trials.

SECONDARY OBJECTIVES:

I. To evaluate the rate of positive outcomes in defined cohorts within treatment trials of treatment combinations including targeted therapies for molecularly defined populations, and also in the subset of treatment trials where the treatments are supported by in vivo models.

II. To perform quality control of the patients registered in the form of pathological confirmation of disease and sub-type to confirm diagnosis and treatment arm allocation.

SECONDARY CORRELATIVE OBJECTIVES:

I. Assess the concordance of the central molecular characterization of the pre-treatment biopsy samples with the genetic readouts from the Designated Laboratories (DLs) for patients enrolled on the ComboMATCH treatment trials.

II. To assess how the registration diagnostic tumor mutation profile and pre-treatment biopsy profile compare to the circulating tumor-derived deoxyribonucleic acid (ctDNA) mutation profile from plasma.

EXPLORATORY OBJECTIVE:

I. Assess association between ComboMATCH treatment trials outcomes (positive or negative) with the type of rationale for the selected drug combinations and the type of rationale for the gene variant/combination for selection (e.g., whether the trial was based on targeted therapies for molecularly defined populations, those that were supported by in vivo models, and those that were supported by empiric clinical data).

OUTLINE:

REGISTRATION: Patients undergo tumor mutational screening of previously-collected tumor samples for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing. Patients who are 18 years or older and have biopsiable disease undergo a new biopsy for research purposes prior to initiating treatment on the ComboMATCH treatment trial.

TREATMENT: Patients with mutations targeted to investigational combination therapies are assigned to 1 of 20 treatment subprotocols.

EAY191-N4: Patients with RAS pathway mutant ovarian or endometrial cancer are randomized to 1 of 2 arms.

ARM I: Patients receive selumetinib PO and olaparib PO on study. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as echocardiogram (ECHO) or multigated acquisition (MUGA), and computed tomography (CT) scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

ARM II: Patients receive selumetinib PO on study. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

EAY191-N2: Patients with inactivating or inferred inactivating NF1 alterations, and hormone receptor positive, HER2-negative metastatic breast cancer. Patients who are fulvestrant naive are assigned to Cohort I, while patients who are fulvestrant resistant are assigned to Cohort II.

COHORT I: Patients are randomized to 1 of 2 arms.

ARM I:Patients receive fulvestrant intramuscularly (IM) on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO twice daily (BID) on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, magnetic resonance imaging (MRI), or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study.

ARM II: Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study.

COHORT II: Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study.

EAY191-E4: Patients with solid tumors who previously underwent taxane therapy.

Patients receive nilotinib hydrochloride monohydrate PO twice daily (BID) on days 1-28 and paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression.

EAY191-A3: Patients with KRAS/NRAS/BRAF mutated low-grade serous ovarian cancer (LGSOC) naive to MEK or CDK4/6 inhibitor therapy are randomized to either combination cohort 1 or monotherapy cohort 1. Patients with LGSOC who have received prior MEK inhibitor therapy are assigned to combination cohort 2. Patients with KRAS/NRAS/HRAS/non-V600E BRAF mutated pancreatic cancer are assigned to combination cohort 3. Patients with all other KRAS/NRAS/HRAS mutated tumor types (excluding LGSOC, non-small cell lung cancer, colorectal cancer, pancreatic, and melanoma) are assigned to combination cohort 4.

COMBINATION COHORTS 1, 2, 3, 4: Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.

MONOTHERAPY COHORT 1: Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.

EAY191-S3: Patients with an activating AKT mutation solid tumor.

Patients receive paclitaxel IV and ipatasertib PO on study. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.

EAY191-A6: Patients with RAS/RAF/MEK/ERK mutant biliary tract cancers are randomized to 1 of 2 arms.

ARM 1: Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo echocardiogram (ECHO) and multigated acquisition scan (MUGA) during screening and on study, a CT with contrast, MRI, or a fludeoxyglucose F-18 positron emission tomography (FDG-PET) during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.

ARM 2: Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.

EAY191-E5: Patients are assigned to 1 of 2 cohorts.

COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.

ARM A: Patients receive sotorasib PO once daily (QD) on days 1-28 and panitumumab intravenously IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.

ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.

COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.

ARM C: Patients receive combination therapy as in Arm A.

EAY191-A2: Patients are assigned to 1 of 3 cohorts.

COHORT 1: PARP-inhibitor naive patients are assigned to Arm A.

ARM A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

COHORT 2: PARP-inhibitor naive patients are randomized to 1 of 2 arms.

ARM B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

ARM C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

COHORT 3: PARP-inhibitor resistant patients are assigned to Arm D.

ARM D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

EAY191-N5: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.

ARM II: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	2900 participants
Allocation:	Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Screening
Official Title:	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Actual Study Start Date :	April 7, 2023
Estimated Primary Completion Date :	July 1, 2030
Estimated Study Completion Date :	July 1, 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Clinical Trials Genetic Testing

Genetic and Rare Diseases Information Center resources: Ovarian Cancer Ovarian Epithelial Cancer Fallopian Tube Cancer

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: EAY191-A2 (Cohort 1, Arm A) Cohort 1, Arm A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.	Drug: Alpelisib Given PO Other Names: BYL719 Phosphoinositide 3-kinase Inhibitor BYL719 Piqray VIJOICE Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Drug: Olaparib Given PO Other Names: AZD 2281 AZD-2281 AZD2281 KU-0059436 Lynparza Olanib Olaparix PARP Inhibitor AZD2281 Procedure: Positron Emission Tomography Undergo PET Other Names: Medical Imaging, Positron Emission Tomography PET PET Scan Positron emission tomography (procedure) Positron Emission Tomography Scan Positron-Emission Tomography proton magnetic resonance spectroscopic imaging PT
Experimental: EAY191-A2 (Cohort 2, Arm B) Cohort 2, Arm B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.	Drug: Alpelisib Given PO Other Names: BYL719 Phosphoinositide 3-kinase Inhibitor BYL719 Piqray VIJOICE Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Drug: Olaparib Given PO Other Names: AZD 2281 AZD-2281 AZD2281 KU-0059436 Lynparza Olanib Olaparix PARP Inhibitor AZD2281 Procedure: Positron Emission Tomography Undergo PET Other Names: Medical Imaging, Positron Emission Tomography PET PET Scan Positron emission tomography (procedure) Positron Emission Tomography Scan Positron-Emission Tomography proton magnetic resonance spectroscopic imaging PT
Experimental: EAY191-A2 (Cohort 2, Arm C) Cohort 2, Arm C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Drug: Olaparib Given PO Other Names: AZD 2281 AZD-2281 AZD2281 KU-0059436 Lynparza Olanib Olaparix PARP Inhibitor AZD2281 Procedure: Positron Emission Tomography Undergo PET Other Names: Medical Imaging, Positron Emission Tomography PET PET Scan Positron emission tomography (procedure) Positron Emission Tomography Scan Positron-Emission Tomography proton magnetic resonance spectroscopic imaging PT
Experimental: EAY191-A2 (Cohort 3, Arm D) Cohort 3, Arm D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.	Drug: Alpelisib Given PO Other Names: BYL719 Phosphoinositide 3-kinase Inhibitor BYL719 Piqray VIJOICE Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Drug: Olaparib Given PO Other Names: AZD 2281 AZD-2281 AZD2281 KU-0059436 Lynparza Olanib Olaparix PARP Inhibitor AZD2281 Procedure: Positron Emission Tomography Undergo PET Other Names: Medical Imaging, Positron Emission Tomography PET PET Scan Positron emission tomography (procedure) Positron Emission Tomography Scan Positron-Emission Tomography proton magnetic resonance spectroscopic imaging PT
Experimental: EAY191-A3 Combo Cohorts 1, 2, 3, 4 (palbociclib, binimetinib) Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Drug: Palbociclib Given PO Other Names: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one Ibrance PD 0332991 PD 332991 PD 991 PD-0332991
Experimental: EAY191-A3 Monotherapy Cohort 1 (binimetinib) Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.	Drug: Binimetinib Given PO Other Names: ARRY-162 ARRY-438162 MEK162 Mektovi Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI
Experimental: EAY191-A6 Arm I (RAS/RAF/MEK/ERK mutations) Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Drug: Fluorouracil Given IV Other Names: 5 Fluorouracil 5 Fluorouracilum 5 FU 5-Fluoro-2,4(1H, 3H)-pyrimidinedione 5-Fluorouracil 5-Fluracil 5-Fu 5FU AccuSite Carac Fluoro Uracil Fluouracil Flurablastin Fluracedyl Fluracil Fluril Fluroblastin Ribofluor Ro 2-9757 Ro-2-9757 Drug: Leucovorin Given IV Other Name: Folinic acid Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning Drug: Oxaliplatin Given IV Other Names: 1-OHP Ai Heng Aiheng Dacotin Dacplat Diaminocyclohexane Oxalatoplatinum Eloxatin Eloxatine JM-83 Oxalatoplatin Oxalatoplatinum RP 54780 RP-54780 SR-96669 Procedure: Positron Emission Tomography Undergo PET Other Names: Medical Imaging, Positron Emission Tomography PET PET Scan Positron emission tomography (procedure) Positron Emission Tomography Scan Positron-Emission Tomography proton magnetic resonance spectroscopic imaging PT
Experimental: EAY191-A6 Arm II (RAS/RAF/MEK/ERK mutations) Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated	Drug: Binimetinib Given PO Other Names: ARRY-162 ARRY-438162 MEK162 Mektovi Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Drug: Fluorouracil Given IV Other Names: 5 Fluorouracil 5 Fluorouracilum 5 FU 5-Fluoro-2,4(1H, 3H)-pyrimidinedione 5-Fluorouracil 5-Fluracil 5-Fu 5FU AccuSite Carac Fluoro Uracil Fluouracil Flurablastin Fluracedyl Fluracil Fluril Fluroblastin Ribofluor Ro 2-9757 Ro-2-9757 Drug: Leucovorin Given IV Other Name: Folinic acid Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning Drug: Oxaliplatin Given IV Other Names: 1-OHP Ai Heng Aiheng Dacotin Dacplat Diaminocyclohexane Oxalatoplatinum Eloxatin Eloxatine JM-83 Oxalatoplatin Oxalatoplatinum RP 54780 RP-54780 SR-96669 Procedure: Positron Emission Tomography Undergo PET Other Names: Medical Imaging, Positron Emission Tomography PET PET Scan Positron emission tomography (procedure) Positron Emission Tomography Scan Positron-Emission Tomography proton magnetic resonance spectroscopic imaging PT
Experimental: EAY191-E4 (taxane therapy) Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Drug: Nilotinib Hydrochloride Monohydrate Given PO Other Names: AMN107 Nilotinib Monohydrochloride Monohydrate Tasigna Drug: Paclitaxel Given PO or IV Other Names: Anzatax Asotax Bristaxol Praxel Taxol Taxol Konzentrat
Experimental: EAY191-E5 Cohort I Arm A (sotorasib, panitumumab) Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Biological: Panitumumab Given IV Other Names: ABX-EGF ABX-EGF Monoclonal Antibody ABX-EGF, Clone E7.6.3 E7.6.3 Human IgG2K Monoclonal Antibody MoAb ABX-EGF MoAb E7.6.3 Monoclonal Antibody ABX-EGF Monoclonal Antibody E7.6.3 Vectibix Drug: Sotorasib Given PO Other Names: AMG 510 AMG-510 AMG510 Lumakras Lumykras
Active Comparator: EAY191-E5 Cohort I Arm B (sotorasib) Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Drug: Sotorasib Given PO Other Names: AMG 510 AMG-510 AMG510 Lumakras Lumykras
Experimental: EAY191-E5 Cohort II (sotorasib) Patients receive combination therapy as in EAY191-E5 Arm A.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Biological: Panitumumab Given IV Other Names: ABX-EGF ABX-EGF Monoclonal Antibody ABX-EGF, Clone E7.6.3 E7.6.3 Human IgG2K Monoclonal Antibody MoAb ABX-EGF MoAb E7.6.3 Monoclonal Antibody ABX-EGF Monoclonal Antibody E7.6.3 Vectibix Drug: Sotorasib Given PO Other Names: AMG 510 AMG-510 AMG510 Lumakras Lumykras
Experimental: EAY191-N2 Cohort I (Arm I) (NF1 mutations) Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, MRI, or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study.	Drug: Binimetinib Given PO Other Names: ARRY-162 ARRY-438162 MEK162 Mektovi Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Drug: Fulvestrant Given IM Other Names: Faslodex Faslodex(ICI 182,780) ICI 182,780 ICI 182780 ZD9238 Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning
Experimental: EAY191-N2 Cohort I (Arm II) (NF1 mutations) Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Drug: Fulvestrant Given IM Other Names: Faslodex Faslodex(ICI 182,780) ICI 182,780 ICI 182780 ZD9238 Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning
Experimental: EAY191-N2 Cohort II (NF1 mutations) Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study.	Drug: Binimetinib Given PO Other Names: ARRY-162 ARRY-438162 MEK162 Mektovi Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Scan Undergo bone scan Other Name: Bone Scintigraphy Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Drug: Fulvestrant Given IM Other Names: Faslodex Faslodex(ICI 182,780) ICI 182,780 ICI 182780 ZD9238 Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning
Experimental: EAY191-N4 Arm I (RAS pathway mutations) Patients receive selumetinib PO and olaparib PO on study. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Marrow Aspiration Undergo bone marrow aspiration Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning Procedure: Mutation Carrier Screening Undergo tumor mutational screening Drug: Olaparib Given PO Other Names: AZD 2281 AZD-2281 AZD2281 KU-0059436 Lynparza Olanib Olaparix PARP Inhibitor AZD2281 Drug: Selumetinib Sulfate Given PO Other Names: AZD-6244 Hydrogen Sulfate AZD6244 Hydrogen Sulfate AZD6244 Hydrogen Sulphate Koselugo Selumetinib Sulphate
Active Comparator: EAY191-N4 Arm II (RAS pathway mutations) Patients receive selumetinib PO on study. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Bone Marrow Aspiration Undergo bone marrow aspiration Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning Procedure: Mutation Carrier Screening Undergo tumor mutational screening Drug: Selumetinib Sulfate Given PO Other Names: AZD-6244 Hydrogen Sulfate AZD6244 Hydrogen Sulfate AZD6244 Hydrogen Sulphate Koselugo Selumetinib Sulphate
Active Comparator: EAY191-N5 Arm I (neratinib maleate) Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning Drug: Neratinib Maleate Given PO Other Names: 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1) HKI-272 Maleate NERATINIB MALEATE ANHYDROUS Nerlynx
Experimental: EAY191-N5 Arm II (neratinib maleate,palbociclib) Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Procedure: Echocardiography Undergo ECHO Other Name: EC Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Procedure: Multigated Acquisition Scan Undergo MUGA Other Names: Blood Pool Scan Equilibrium Radionuclide Angiography Gated Blood Pool Imaging Gated Heart Pool Scan MUGA MUGA Scan Multi-Gated Acquisition Scan Radionuclide Ventriculogram Scan Radionuclide Ventriculography RNVG SYMA Scanning Synchronized Multigated Acquisition Scanning Drug: Neratinib Maleate Given PO Other Names: 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1) HKI-272 Maleate NERATINIB MALEATE ANHYDROUS Nerlynx Drug: Palbociclib Given PO Other Names: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one Ibrance PD 0332991 PD 332991 PD 991 PD-0332991
Experimental: EAY191-S3 (activating AKT mutation) Patients receive paclitaxel IV and ipatasertib PO on study. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.	Procedure: Biopsy Undergo biopsy Other Names: BIOPSY_TYPE Bx Procedure: Biospecimen Collection Undergo blood collection Other Names: Biological Sample Collection Biospecimen Collected Specimen Collection Procedure: Computed Tomography Undergo CT Other Names: CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized axial tomography (procedure) Computerized Tomography Computerized Tomography (CT) scan CT CT Scan tomography Drug: Ipatasertib Given PO Other Names: GDC-0068 RG-7440 Procedure: Magnetic Resonance Imaging Undergo MRI Other Names: Magnetic Resonance Magnetic Resonance Imaging (MRI) Magnetic resonance imaging (procedure) Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan MRIs NMR Imaging NMRI Nuclear Magnetic Resonance Imaging sMRI Structural MRI Drug: Paclitaxel Given PO or IV Other Names: Anzatax Asotax Bristaxol Praxel Taxol Taxol Konzentrat

Outcome Measures

Primary Outcome Measures :

Accrual of patients to ComboMATCH treatment trials [ Time Frame: Up to 8 years ]
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).
Assignment of patients to ComboMATCH treatment trials [ Time Frame: Up to 8 years ]
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).
Enrollment rates to ComboMATCH treatment trials [ Time Frame: Up to 8 years ]
Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).

Secondary Outcome Measures :

Rate of positive outcomes within the treatment trial defined cohorts [ Time Frame: Up to 8 years ]
For each cohort in each treatment trial there is a defined primary efficacy endpoint (usually progression free survival [PFS] or overall response rate) and defined primary analysis for evaluating the primary endpoint. As cohorts are completed, whether they meet the criteria for a positive primary outcome will be determined. Positive treatment cohort outcome (on primary endpoint) will be analyzed as a binary random variable. The raw proportion of treatment cohorts with positive outcomes and an exact binomial confidence interval will be computed. If there are a sufficient number of treatment cohorts, logistic regression analysis will be performed examining the relationship of treatment cohort characteristics with successful outcomes. The goal is to achieve a rate of at least 30% with positive outcomes, both overall and in the subset of treatment trials based on in vivo models.

Other Outcome Measures:

Concordance between whole exome sequencing (WES) and results from the Designated Laboratory (DL) [ Time Frame: Up to 8 years ]
Whole exome and other sequencing will be performed on mandatory tissue biopsies or, if no biopsy tissue is available, on submitted formalin-fixed paraffin-embedded tissue. These assays will be done in a clinical laboratory (e.g., Clinical Laboratory Improvement Act-compliant); but results will not be returned to the clinical site. Results will be used to compare with the DL assay results. This comparison will be required to conduct an important secondary analysis of the primary endpoint in each cohort in each treatment trial, restricting to those cases that are concordant between WES and the result from the DL that was the basis for enrollment (integrated).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient must have measurable disease
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky performance status of >= 50%
Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)
Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:
- Patients must have progressed on at least one line of standard systemic therapy OR
- Patients whose disease has no standard treatment that has been shown to prolong overall survival
Patient must meet one of the following requirements:
- Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial OR
- Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:
  - Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial
  - Patient must not have had a Response Evaluation Criteria in Solid Tumors (RECIST) response (complete response [CR] or partial response [PR]) to any intervening therapy after collection of the tissue
  - Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available OR
- Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:
  - Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available
- NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions. Performance of the mandatory research biopsy or submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only
NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05564377

Locations

Show 363 study locations

Layout table for location information

United States, Alabama
University of Alabama at Birmingham Cancer Center	Recruiting
Birmingham, Alabama, United States, 35233
Contact: Site Public Contact 205-934-0220 tmyrick@uab.edu
Principal Investigator: Rebecca C. Arend
University of South Alabama Mitchell Cancer Institute	Recruiting
Mobile, Alabama, United States, 36688
Contact: Site Public Contact 251-445-9870 pfrancisco@usouthal.edu
Principal Investigator: Ahmed Abdalla
United States, Arizona
CTCA at Western Regional Medical Center	Recruiting
Goodyear, Arizona, United States, 85338
Contact: Site Public Contact 623-207-3000
Principal Investigator: Sagun Shrestha
Kingman Regional Medical Center	Recruiting
Kingman, Arizona, United States, 86401
Contact: Site Public Contact 702-384-0013 research@sncrf.org
Principal Investigator: John A. Ellerton
Mayo Clinic Hospital in Arizona	Recruiting
Phoenix, Arizona, United States, 85054
Contact: Site Public Contact 855-776-0015
Principal Investigator: Aaron S. Mansfield
United States, California
PCR Oncology	Recruiting
Arroyo Grande, California, United States, 93420
Contact: Site Public Contact 702-384-0013 research@sncrf.org
Principal Investigator: John A. Ellerton
Mercy Cancer Center - Carmichael	Recruiting
Carmichael, California, United States, 95608
Contact: Site Public Contact 720-874-1881 ResearchInstituteInquiries@CommonSpirit.org
Principal Investigator: Shahzad Siddique
Mercy San Juan Medical Center	Recruiting
Carmichael, California, United States, 95608
Contact: Site Public Contact 916-556-3301 OncologyResearch@DignityHealth.org
Principal Investigator: Shahzad Siddique
Epic Care-Dublin	Recruiting
Dublin, California, United States, 94568
Contact: Site Public Contact 925-875-1677
Principal Investigator: Lisa Bailey
Mercy Cancer Center - Elk Grove	Recruiting
Elk Grove, California, United States, 95758
Contact: Site Public Contact 720-874-1881 ResearchInstituteInquiries@CommonSpirit.org
Principal Investigator: Shahzad Siddique
Contra Costa Regional Medical Center	Recruiting
Martinez, California, United States, 94553-3156
Contact: Site Public Contact 925-957-5400
Principal Investigator: Lisa Bailey
Saint Joseph Hospital - Orange	Recruiting
Orange, California, United States, 92868
Contact: Site Public Contact 714-734-6220
Principal Investigator: Timothy E. Byun
Stanford Cancer Institute Palo Alto	Recruiting
Palo Alto, California, United States, 94304
Contact: Site Public Contact 650-498-7061 ccto-office@stanford.edu
Principal Investigator: James M. Ford
Mercy Cancer Center - Rocklin	Recruiting
Rocklin, California, United States, 95765
Contact: Site Public Contact 720-874-1881 ResearchInstituteInquiries@CommonSpirit.org
Principal Investigator: Shahzad Siddique
Mercy Cancer Center - Sacramento	Recruiting
Sacramento, California, United States, 95816
Contact: Site Public Contact 720-874-1881 ResearchInstituteInquiries@CommonSpirit.org
Principal Investigator: Shahzad Siddique
Sharp Memorial Hospital	Recruiting
San Diego, California, United States, 92123
Contact: Site Public Contact 858-939-5062 cathy.wood@sharp.com
Principal Investigator: Charles H. Redfern
UCSF Medical Center-Mission Bay	Recruiting
San Francisco, California, United States, 94158
Contact: Site Public Contact 877-827-3222 cancertrials@ucsf.edu
Principal Investigator: Arun A. Rangaswami
Saint John's Cancer Institute	Recruiting
Santa Monica, California, United States, 90404
Contact: Site Public Contact 310-582-7448
Principal Investigator: Reva K. Basho
Epic Care Cyberknife Center	Recruiting
Walnut Creek, California, United States, 94597
Contact: Site Public Contact 510-465-8016 somega@bati.org
Principal Investigator: Lisa Bailey
Presbyterian Intercommunity Hospital	Recruiting
Whittier, California, United States, 90602
Contact: Site Public Contact 562-698-0811
Principal Investigator: Christopher R. Foss
Woodland Memorial Hospital	Recruiting
Woodland, California, United States, 95695
Contact: Site Public Contact 720-874-1881 ResearchInstituteInquiries@CommonSpirit.org
Principal Investigator: Shahzad Siddique
United States, Colorado
UCHealth University of Colorado Hospital	Recruiting
Aurora, Colorado, United States, 80045
Contact: Site Public Contact 720-848-0650
Principal Investigator: Robert W. Lentz
Poudre Valley Hospital	Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Site Public Contact 970-297-6150
Principal Investigator: Robert W. Lentz
Cancer Care and Hematology-Fort Collins	Recruiting
Fort Collins, Colorado, United States, 80528
Contact: Site Public Contact ecog.rss@jimmy.harvard.edu
Principal Investigator: Robert W. Lentz
UCHealth Greeley Hospital	Recruiting
Greeley, Colorado, United States, 80631
Contact: Site Public Contact ecog.rss@jimmy.harvard.edu
Principal Investigator: Robert W. Lentz
Medical Center of the Rockies	Recruiting
Loveland, Colorado, United States, 80538
Contact: Site Public Contact 970-203-7083
Principal Investigator: Robert W. Lentz
United States, Delaware
Helen F Graham Cancer Center	Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact 302-623-4450 lbarone@christianacare.org
Principal Investigator: Gregory A. Masters
Medical Oncology Hematology Consultants PA	Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact 302-623-4450 lbarone@christianacare.org
Principal Investigator: Gregory A. Masters
United States, Florida
UM Sylvester Comprehensive Cancer Center at Aventura	Recruiting
Aventura, Florida, United States, 33180
Contact: Site Public Contact 954-461-2180
Principal Investigator: Chukwuemeka (Emeka) V. Ikpeazu
UM Sylvester Comprehensive Cancer Center at Coral Gables	Recruiting
Coral Gables, Florida, United States, 33146
Contact: Site Public Contact 305-243-2647
Principal Investigator: Chukwuemeka (Emeka) V. Ikpeazu
UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Recruiting
Deerfield Beach, Florida, United States, 33442
Contact: Site Public Contact 305-243-2647
Principal Investigator: Chukwuemeka (Emeka) V. Ikpeazu
Broward Health Medical Center	Recruiting
Fort Lauderdale, Florida, United States, 33316
Contact: Site Public Contact 302-651-5572 Allison.bruce@nemours.org
Principal Investigator: Mehmet F. Hepgur
University of Florida Health Science Center - Gainesville	Recruiting
Gainesville, Florida, United States, 32610
Contact: Site Public Contact 352-273-8010 cancer-center@ufl.edu
Principal Investigator: Thomas J. George
Mayo Clinic in Florida	Recruiting
Jacksonville, Florida, United States, 32224-9980
Contact: Site Public Contact 855-776-0015
Principal Investigator: Aaron S. Mansfield
University of Miami Miller School of Medicine-Sylvester Cancer Center	Recruiting
Miami, Florida, United States, 33136
Contact: Site Public Contact 305-243-2647
Principal Investigator: Chukwuemeka (Emeka) V. Ikpeazu
UM Sylvester Comprehensive Cancer Center at Kendall	Recruiting
Miami, Florida, United States, 33176
Contact: Site Public Contact 305-243-2647
Principal Investigator: Chukwuemeka (Emeka) V. Ikpeazu
UM Sylvester Comprehensive Cancer Center at Plantation	Recruiting
Plantation, Florida, United States, 33324
Contact: Site Public Contact 305-243-2647
Principal Investigator: Chukwuemeka (Emeka) V. Ikpeazu
United States, Georgia
CTCA at Southeastern Regional Medical Center	Recruiting
Newnan, Georgia, United States, 30265
Contact: Site Public Contact 770-400-6629
Principal Investigator: Natalie S. Godbee
United States, Hawaii
Hawaii Cancer Care - Westridge	Recruiting
'Aiea, Hawaii, United States, 96701
Contact: Site Public Contact 808-539-2273 info@hawaiicancercare.com
Principal Investigator: Jeffrey L. Berenberg
Pali Momi Medical Center	Recruiting
'Aiea, Hawaii, United States, 96701
Contact: Site Public Contact 808-486-6000
Principal Investigator: Jeffrey L. Berenberg
Hawaii Cancer Care Inc - Waterfront Plaza	Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact 808-524-6115 i.webster@hawaiicancercare.com
Principal Investigator: Jeffrey L. Berenberg
Queen's Cancer Cenrer - POB I	Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact 808-532-0315
Principal Investigator: Jeffrey L. Berenberg
Queen's Medical Center	Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact 808-545-8548
Principal Investigator: Jeffrey L. Berenberg
Straub Clinic and Hospital	Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact 808-522-4333
Principal Investigator: Jeffrey L. Berenberg
Queen's Cancer Center - Kuakini	Recruiting
Honolulu, Hawaii, United States, 96817
Contact: Site Public Contact 808-531-8521
Principal Investigator: Jeffrey L. Berenberg
Kapiolani Medical Center for Women and Children	Recruiting
Honolulu, Hawaii, United States, 96826
Contact: Site Public Contact 808-983-6090
Principal Investigator: Jeffrey L. Berenberg
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise	Recruiting
Boise, Idaho, United States, 83706
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org
Principal Investigator: John M. Schallenkamp
Saint Luke's Cancer Institute - Boise	Recruiting
Boise, Idaho, United States, 83712
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org
Principal Investigator: Alison K. Conlin
Saint Alphonsus Cancer Care Center-Caldwell	Recruiting
Caldwell, Idaho, United States, 83605
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org
Principal Investigator: John M. Schallenkamp
Kootenai Health - Coeur d'Alene	Recruiting
Coeur d'Alene, Idaho, United States, 83814
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Saint Luke's Cancer Institute - Fruitland	Recruiting
Fruitland, Idaho, United States, 83619
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org
Principal Investigator: Alison K. Conlin
Saint Luke's Cancer Institute - Meridian	Recruiting
Meridian, Idaho, United States, 83642
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org
Principal Investigator: Alison K. Conlin
Saint Luke's Cancer Institute - Nampa	Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org
Principal Investigator: Alison K. Conlin
Saint Alphonsus Cancer Care Center-Nampa	Recruiting
Nampa, Idaho, United States, 83687
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Kootenai Clinic Cancer Services - Post Falls	Recruiting
Post Falls, Idaho, United States, 83854
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Kootenai Cancer Clinic	Recruiting
Sandpoint, Idaho, United States, 83864
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Saint Luke's Cancer Institute - Twin Falls	Recruiting
Twin Falls, Idaho, United States, 83301
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org
Principal Investigator: Alison K. Conlin
United States, Illinois
Advocate Good Shepherd Hospital	Recruiting
Barrington, Illinois, United States, 60010
Contact: Site Public Contact 847-842-4847
Principal Investigator: Antony Ruggeri
Illinois CancerCare-Bloomington	Recruiting
Bloomington, Illinois, United States, 61704
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Illinois CancerCare-Canton	Recruiting
Canton, Illinois, United States, 61520
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Illinois CancerCare-Carthage	Recruiting
Carthage, Illinois, United States, 62321
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Centralia Oncology Clinic	Recruiting
Centralia, Illinois, United States, 62801
Contact: Site Public Contact 217-876-4762 morganthaler.jodi@mhsil.com
Principal Investigator: Bryan A. Faller
Northwestern University	Recruiting
Chicago, Illinois, United States, 60611
Contact: Site Public Contact 312-695-1301 cancer@northwestern.edu
Principal Investigator: Devalingam Mahalingam
John H Stroger Jr Hospital of Cook County	Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact 312-864-5204
Principal Investigator: Thomas E. Lad
University of Chicago Comprehensive Cancer Center	Recruiting
Chicago, Illinois, United States, 60637
Contact: Site Public Contact 773-702-8222 cancerclinicaltrials@bsd.uchicago.edu
Principal Investigator: Ardaman Shergill
Advocate Illinois Masonic Medical Center	Recruiting
Chicago, Illinois, United States, 60657
Contact: Site Public Contact 773-296-5360
Principal Investigator: Antony Ruggeri
AMG Crystal Lake - Oncology	Recruiting
Crystal Lake, Illinois, United States, 60014
Contact: Site Public Contact 630-929-6129 advocateresearch@advocate.com
Principal Investigator: Antony Ruggeri
Carle at The Riverfront	Recruiting
Danville, Illinois, United States, 61832
Contact: Site Public Contact 800-446-5532 Research@Carle.com
Principal Investigator: Tanmay Sahai
Cancer Care Specialists of Illinois - Decatur	Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact 217-876-4762 morganthaler.jodi@mhsil.com
Principal Investigator: Bryan A. Faller
Decatur Memorial Hospital	Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact 217-876-4762 morganthaler.jodi@mhsil.com
Principal Investigator: Bryan A. Faller
Northwestern Medicine Cancer Center Kishwaukee	Recruiting
DeKalb, Illinois, United States, 60115
Contact: Site Public Contact 630-352-5360 Donald.Smith3@nm.org
Principal Investigator: Devalingam Mahalingam
Illinois CancerCare-Dixon	Recruiting
Dixon, Illinois, United States, 61021
Contact: Site Public Contact 815-285-7800
Principal Investigator: Bryan A. Faller
Advocate Good Samaritan Hospital	Recruiting
Downers Grove, Illinois, United States, 60515
Contact: Site Public Contact 630-275-1270 Barbara.barhamand@advocatehealth.com
Principal Investigator: Antony Ruggeri
Carle Physician Group-Effingham	Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact 800-446-5532 Research@carle.com
Principal Investigator: Tanmay Sahai
Crossroads Cancer Center	Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact 217-876-4762 morganthaler.jodi@mhsil.com
Principal Investigator: Bryan A. Faller
Advocate Sherman Hospital	Recruiting
Elgin, Illinois, United States, 60123
Contact: Site Public Contact 847-429-2907
Principal Investigator: Antony Ruggeri
Illinois CancerCare-Eureka	Recruiting
Eureka, Illinois, United States, 61530
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Illinois CancerCare-Galesburg	Recruiting
Galesburg, Illinois, United States, 61401
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Northwestern Medicine Cancer Center Delnor	Recruiting
Geneva, Illinois, United States, 60134
Contact: Site Public Contact 630-352-5360 Donald.Smith3@nm.org
Principal Investigator: Devalingam Mahalingam
Advocate South Suburban Hospital	Recruiting
Hazel Crest, Illinois, United States, 60429
Contact: Site Public Contact 708-799-9995
Principal Investigator: Antony Ruggeri
Illinois CancerCare-Kewanee Clinic	Recruiting
Kewanee, Illinois, United States, 61443
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Northwestern Medicine Lake Forest Hospital	Recruiting
Lake Forest, Illinois, United States, 60045
Contact: Site Public Contact cancertrials@northwestern.edu
Principal Investigator: Devalingam Mahalingam
AMG Libertyville - Oncology	Recruiting
Libertyville, Illinois, United States, 60048
Contact: Site Public Contact 630-929-6129 advocateresearch@advocatehealth.com
Principal Investigator: Antony Ruggeri
Condell Memorial Hospital	Recruiting
Libertyville, Illinois, United States, 60048
Contact: Site Public Contact 630-929-6129 advocateresearch@advocatehealth.com
Principal Investigator: Antony Ruggeri
Illinois CancerCare-Macomb	Recruiting
Macomb, Illinois, United States, 61455
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Carle Physician Group-Mattoon/Charleston	Recruiting
Mattoon, Illinois, United States, 61938
Contact: Site Public Contact 800-446-5532 Research@carle.com
Principal Investigator: Tanmay Sahai
UC Comprehensive Cancer Center at Silver Cross	Recruiting
New Lenox, Illinois, United States, 60451
Contact: Site Public Contact 773-702-8222 cancerclinicaltrials@bsd.uchicago.edu
Principal Investigator: Ardaman Shergill
Cancer Care Center of O'Fallon	Recruiting
O'Fallon, Illinois, United States, 62269
Contact: Site Public Contact 217-876-4762 morganthaler.jodi@mhsil.com
Principal Investigator: Bryan A. Faller
Advocate Christ Medical Center	Recruiting
Oak Lawn, Illinois, United States, 60453-2699
Contact: Site Public Contact 800-323-8622
Principal Investigator: Antony Ruggeri
Northwestern Medicine Orland Park	Recruiting
Orland Park, Illinois, United States, 60462
Contact: Site Public Contact nctnprogram_rhlccc@northwestern.edu
Principal Investigator: Devalingam Mahalingam
University of Chicago Medicine-Orland Park	Recruiting
Orland Park, Illinois, United States, 60462
Contact: Site Public Contact 773-702-8222 cancerclinicaltrials@bsd.uchicago.edu
Principal Investigator: Ardaman Shergill
Illinois CancerCare-Ottawa Clinic	Recruiting
Ottawa, Illinois, United States, 61350
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Advocate Lutheran General Hospital	Recruiting
Park Ridge, Illinois, United States, 60068
Contact: Site Public Contact 847-384-3621
Principal Investigator: Antony Ruggeri
Illinois CancerCare-Pekin	Recruiting
Pekin, Illinois, United States, 61554
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Illinois CancerCare-Peoria	Recruiting
Peoria, Illinois, United States, 61615
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Illinois CancerCare-Peru	Recruiting
Peru, Illinois, United States, 61354
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Illinois CancerCare-Princeton	Recruiting
Princeton, Illinois, United States, 61356
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Memorial Hospital East	Recruiting
Shiloh, Illinois, United States, 62269
Contact: Site Public Contact 314-747-9912 dschwab@wustl.edu
Principal Investigator: Nusayba Bagegni
Southern Illinois University School of Medicine	Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact 217-545-7929
Principal Investigator: Bryan A. Faller
Springfield Clinic	Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact 800-444-7541
Principal Investigator: Bryan A. Faller
Memorial Medical Center	Recruiting
Springfield, Illinois, United States, 62781
Contact: Site Public Contact 217-528-7541 pallante.beth@mhsil.com
Principal Investigator: Bryan A. Faller
Carle Cancer Center	Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact 800-446-5532 Research@carle.com
Principal Investigator: Tanmay Sahai
Northwestern Medicine Cancer Center Warrenville	Recruiting
Warrenville, Illinois, United States, 60555
Contact: Site Public Contact 630-352-5360 Donald.Smith3@nm.org
Principal Investigator: Devalingam Mahalingam
Illinois CancerCare - Washington	Recruiting
Washington, Illinois, United States, 61571
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com
Principal Investigator: Bryan A. Faller
Midwestern Regional Medical Center	Recruiting
Zion, Illinois, United States, 60099
Contact: Site Public Contact 844-793-0745
Principal Investigator: Evan Pisick
United States, Iowa
Mission Cancer and Blood - Ankeny	Recruiting
Ankeny, Iowa, United States, 50023
Contact: Site Public Contact 515-282-2921
Principal Investigator: Richard L. Deming
Mercy Hospital	Recruiting
Cedar Rapids, Iowa, United States, 52403
Contact: Site Public Contact 319-365-4673
Principal Investigator: Deborah W. Wilbur
Oncology Associates at Mercy Medical Center	Recruiting
Cedar Rapids, Iowa, United States, 52403
Contact: Site Public Contact 319-363-2690
Principal Investigator: Deborah W. Wilbur
Medical Oncology and Hematology Associates-Des Moines	Recruiting
Des Moines, Iowa, United States, 50309
Contact: Site Public Contact 515-241-3305
Principal Investigator: Joshua Lukenbill
Mercy Medical Center - Des Moines	Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact 515-358-6613 cancerresearch@mercydesmoines.org
Principal Investigator: Richard L. Deming
United States, Kentucky
Saint Joseph Hospital East	Recruiting
Lexington, Kentucky, United States, 40509
Contact: Site Public Contact 720-874-1881 ResearchInstituteInquiries@CommonSpirit.org
Principal Investigator: Shahzad Siddique
University of Kentucky/Markey Cancer Center	Recruiting
Lexington, Kentucky, United States, 40536
Contact: Site Public Contact 859-257-3379
Principal Investigator: Susanne M. Arnold
Mercy Health - Paducah Medical Oncology and Hematology	Recruiting
Paducah, Kentucky, United States, 42003
Contact: Site Public Contact 270-538-5632 BJWarner@mercy.com
Principal Investigator: Nicholas DiBella
United States, Louisiana
Ochsner Medical Center Jefferson	Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Site Public Contact 504-842-8084 Elisemarie.curry@ochsner.org
Principal Investigator: John T. Cole
United States, Maine
Harold Alfond Center for Cancer Care	Recruiting
Augusta, Maine, United States, 04330
Contact: Site Public Contact 207-626-4855
Principal Investigator: Leslie S. Bradford
Lafayette Family Cancer Center-EMMC	Recruiting
Brewer, Maine, United States, 04412
Contact: Site Public Contact 800-987-3005
Principal Investigator: Sarah J. Sinclair
Maine Medical Center- Scarborough Campus	Recruiting
Scarborough, Maine, United States, 04074
Contact: Site Public Contact 207-396-8090 wrighd@mmc.org
Principal Investigator: Leslie S. Bradford
Maine Medical Partners - South Portland	Recruiting
South Portland, Maine, United States, 04106
Contact: Site Public Contact 207-396-8670 ClinicalResearch@mmc.org
Principal Investigator: Leslie S. Bradford
United States, Maryland
National Institutes of Health Clinical Center	Recruiting
Bethesda, Maryland, United States, 20892
Contact: Site Public Contact 800-411-1222
Principal Investigator: A P. Chen
UPMC Western Maryland	Recruiting
Cumberland, Maryland, United States, 21502
Contact: Site Public Contact 240-964-1400
Principal Investigator: Adam M. Brufsky
United States, Massachusetts
Tufts Medical Center	Recruiting
Boston, Massachusetts, United States, 02111
Contact: Site Public Contact 617-636-5000 ContactUsCancerCenter@TuftsMedicalCenter.org
Principal Investigator: Rachel J. Buchsbaum
Dana-Farber Cancer Institute	Recruiting
Boston, Massachusetts, United States, 02215
Contact: Site Public Contact 877-442-3324
Principal Investigator: Geoffrey I. Shapiro
Baystate Medical Center	Recruiting
Springfield, Massachusetts, United States, 01199
Contact: Site Public Contact 413-794-3565 tamara.wrenn@baystatehealth.org
Principal Investigator: Tashanna K. Myers
United States, Michigan
Saint Joseph Mercy Hospital	Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Bronson Battle Creek	Recruiting
Battle Creek, Michigan, United States, 49017
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Saint Joseph Mercy Brighton	Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Trinity Health IHA Medical Group Hematology Oncology - Brighton	Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Saint Joseph Mercy Canton	Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Trinity Health IHA Medical Group Hematology Oncology - Canton	Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Saint Joseph Mercy Chelsea	Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Beaumont Hospital - Dearborn	Recruiting
Dearborn, Michigan, United States, 48124
Contact: Site Public Contact 248-551-7695
Principal Investigator: Dana Zakalik
Beaumont Hospital - Farmington Hills	Recruiting
Farmington Hills, Michigan, United States, 48336
Contact: Site Public Contact 248-551-7695
Principal Investigator: Dana Zakalik
Genesee Cancer and Blood Disease Treatment Center	Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact 810-762-8038 wstrong@ghci.org
Principal Investigator: Tareq Al Baghdadi
Genesee Hematology Oncology PC	Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact 810-762-8038 wstrong@ghci.org
Principal Investigator: Tareq Al Baghdadi
Genesys Hurley Cancer Institute	Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact 810-762-8038 wstrong@ghci.org
Principal Investigator: Tareq Al Baghdadi
Hurley Medical Center	Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact 810-762-8038 wstrong@ghci.org
Principal Investigator: Tareq Al Baghdadi
Spectrum Health at Butterworth Campus	Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Trinity Health Grand Rapids Hospital	Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Bronson Methodist Hospital	Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
West Michigan Cancer Center	Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Ascension Borgess Cancer Center	Recruiting
Kalamazoo, Michigan, United States, 49009
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Borgess Medical Center	Recruiting
Kalamazoo, Michigan, United States, 49048
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
University of Michigan Health - Sparrow Lansing	Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact 517-364-3712 harsha.trivedi@umhsparrow.org
Principal Investigator: Tareq Al Baghdadi
Trinity Health Saint Mary Mercy Livonia Hospital	Recruiting
Livonia, Michigan, United States, 48154
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Great Lakes Cancer Management Specialists-Macomb Medical Campus	Recruiting
Macomb, Michigan, United States, 48044
Contact: Site Public Contact 313-343-3166 karen.forman@ascension.org
Principal Investigator: Tareq Al Baghdadi
Trinity Health Muskegon Hospital	Recruiting
Muskegon, Michigan, United States, 49444
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Cancer and Hematology Centers of Western Michigan - Norton Shores	Recruiting
Norton Shores, Michigan, United States, 49444
Contact: Site Public Contact 616-391-1230 connie.szczepanek@crcwm.org
Principal Investigator: Kathleen J. Yost
21st Century Oncology-Pontiac	Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact 248-858-6215 Emily.Crofts@trinity-health.org
Principal Investigator: Tareq Al Baghdadi
Saint Joseph Mercy Oakland	Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Corewell Health Reed City Hospital	Recruiting
Reed City, Michigan, United States, 49677
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Beaumont Children's Hospital-Royal Oak	Recruiting
Royal Oak, Michigan, United States, 48073
Contact: Site Public Contact 248-551-7695
Principal Investigator: Dana Zakalik
William Beaumont Hospital-Royal Oak	Recruiting
Royal Oak, Michigan, United States, 48073
Contact: Site Public Contact 248-551-7695
Principal Investigator: Dana Zakalik
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Lakeland Medical Center Saint Joseph	Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Munson Medical Center	Recruiting
Traverse City, Michigan, United States, 49684
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
William Beaumont Hospital - Troy	Recruiting
Troy, Michigan, United States, 48085
Contact: Site Public Contact 248-551-7695
Principal Investigator: Dana Zakalik
University of Michigan Health - West	Recruiting
Wyoming, Michigan, United States, 49519
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org
Principal Investigator: Kathleen J. Yost
Huron Gastroenterology PC	Recruiting
Ypsilanti, Michigan, United States, 48106
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Recruiting
Ypsilanti, Michigan, United States, 48197
Contact: Site Public Contact 734-712-7251 MCRCwebsitecontactform@stjoeshealth.org
Principal Investigator: Tareq Al Baghdadi
United States, Minnesota
Sanford Joe Lueken Cancer Center	Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Site Public Contact 218-333-5000 OncologyClinicalTrialsFargo@sanfordhealth.org
Principal Investigator: Daniel Almquist
Mercy Hospital	Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com
Principal Investigator: David M. King
Essentia Health - Deer River Clinic	Recruiting
Deer River, Minnesota, United States, 56636
Contact: Site Public Contact 218-786-3308 CancerTrials@EssentiaHealth.org
Principal Investigator: Bret E. Friday
Essentia Health Cancer Center	Recruiting
Duluth, Minnesota, United States, 55805
Contact: Site Public Contact 218-786-3308 CancerTrials@EssentiaHealth.org
Principal Investigator: Bret E. Friday
Fairview Southdale Hospital	Recruiting
Edina, Minnesota, United States, 55435
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com
Principal Investigator: David M. King
Essentia Health Hibbing Clinic	Recruiting
Hibbing, Minnesota, United States, 55746
Contact: Site Public Contact 218-786-3308
Principal Investigator: Bret E. Friday
Abbott-Northwestern Hospital	Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com
Principal Investigator: David M. King
Mayo Clinic in Rochester	Recruiting
Rochester, Minnesota, United States, 55905
Contact: Site Public Contact 855-776-0015
Principal Investigator: Aaron S. Mansfield
Park Nicollet Clinic - Saint Louis Park	Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com
Principal Investigator: David M. King
Regions Hospital	Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com
Principal Investigator: David M. King
United Hospital	Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com
Principal Investigator: David M. King
Essentia Health Sandstone	Recruiting
Sandstone, Minnesota, United States, 55072
Contact: Site Public Contact 218-786-3308 CancerTrials@EssentiaHealth.org
Principal Investigator: Bret E. Friday
Essentia Health Virginia Clinic	Recruiting
Virginia, Minnesota, United States, 55792
Contact: Site Public Contact 218-786-3308 CancerTrials@EssentiaHealth.org
Principal Investigator: Bret E. Friday
United States, Mississippi
Gulfport Memorial Hospital	Recruiting
Gulfport, Mississippi, United States, 39502
Contact: Site Public Contact 504-210-3539 emede1@lsuhsc.edu
Principal Investigator: Augusto C. Ochoa
United States, Missouri
Saint Francis Medical Center	Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact 573-334-2230 sfmc@sfmc.net
Principal Investigator: Bryan A. Faller
Saint Luke's Hospital	Recruiting
Chesterfield, Missouri, United States, 63017
Contact: Site Public Contact 314-205-6936
Principal Investigator: Joseph Sokhn
Siteman Cancer Center at West County Hospital	Recruiting
Creve Coeur, Missouri, United States, 63141
Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu
Principal Investigator: Nusayba Bagegni
Parkland Health Center - Farmington	Recruiting
Farmington, Missouri, United States, 63640
Contact: Site Public Contact 314-996-5569
Principal Investigator: Bryan A. Faller
Washington University School of Medicine	Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu
Principal Investigator: Nusayba Bagegni
Siteman Cancer Center-South County	Recruiting
Saint Louis, Missouri, United States, 63129
Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu
Principal Investigator: Nusayba Bagegni
Missouri Baptist Medical Center	Recruiting
Saint Louis, Missouri, United States, 63131
Contact: Site Public Contact 314-996-5569
Principal Investigator: Bryan A. Faller
Siteman Cancer Center at Christian Hospital	Recruiting
Saint Louis, Missouri, United States, 63136
Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu
Principal Investigator: Nusayba Bagegni
Mercy Hospital Saint Louis	Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Site Public Contact 314-251-7066
Principal Investigator: Jay W. Carlson
Siteman Cancer Center at Saint Peters Hospital	Recruiting
Saint Peters, Missouri, United States, 63376
Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu
Principal Investigator: Nusayba Bagegni
Sainte Genevieve County Memorial Hospital	Recruiting
Sainte Genevieve, Missouri, United States, 63670
Contact: Site Public Contact 314-996-5569
Principal Investigator: Bryan A. Faller
Missouri Baptist Sullivan Hospital	Recruiting
Sullivan, Missouri, United States, 63080
Contact: Site Public Contact 314-996-5569
Principal Investigator: Bryan A. Faller
BJC Outpatient Center at Sunset Hills	Recruiting
Sunset Hills, Missouri, United States, 63127
Contact: Site Public Contact 314-996-5569
Principal Investigator: Bryan A. Faller
United States, Montana
Community Hospital of Anaconda	Recruiting
Anaconda, Montana, United States, 59711
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Billings Clinic Cancer Center	Recruiting
Billings, Montana, United States, 59101
Contact: Site Public Contact 800-996-2663 research@billingsclinic.org
Principal Investigator: John M. Schallenkamp
Bozeman Deaconess Hospital	Recruiting
Bozeman, Montana, United States, 59715
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Benefis Healthcare- Sletten Cancer Institute	Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Kalispell Regional Medical Center	Recruiting
Kalispell, Montana, United States, 59901
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Community Medical Hospital	Recruiting
Missoula, Montana, United States, 59804
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
United States, Nevada
OptumCare Cancer Care at Charleston	Recruiting
Las Vegas, Nevada, United States, 89102
Contact: Site Public Contact 702-384-0013 research@sncrf.org
Principal Investigator: John A. Ellerton
Alliance for Childhood Diseases/Cure 4 the Kids Foundation	Recruiting
Las Vegas, Nevada, United States, 89135
Contact: Site Public Contact 702-384-0013 research@sncrf.org
Principal Investigator: John A. Ellerton
Summerlin Hospital Medical Center	Recruiting
Las Vegas, Nevada, United States, 89144
Contact: Site Public Contact 702-384-0013 research@sncrf.org
Principal Investigator: John A. Ellerton
OptumCare Cancer Care at Fort Apache	Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact 702-384-0013 research@sncrf.org
Principal Investigator: John A. Ellerton
Renown Regional Medical Center	Recruiting
Reno, Nevada, United States, 89502
Contact: Site Public Contact 702-384-0013 research@sncrf.org
Principal Investigator: John A. Ellerton
United States, New Jersey
Monmouth Medical Center Southern Campus	Recruiting
Lakewood, New Jersey, United States, 08701
Contact: Site Public Contact 732-923-6564 mary.danish@rwjbh.org
Principal Investigator: Shridar Ganesan
Monmouth Medical Center	Recruiting
Long Branch, New Jersey, United States, 07740
Contact: Site Public Contact 732-923-6564 mary.danish@rwjbh.org
Principal Investigator: Shridar Ganesan
Memorial Sloan Kettering Monmouth	Recruiting
Middletown, New Jersey, United States, 07748
Contact: Site Public Contact 212-639-7592
Principal Investigator: Claire F. Friedman
Rutgers Cancer Institute of New Jersey	Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Site Public Contact 732-235-7356
Principal Investigator: Shridar Ganesan
Capital Health Medical Center-Hopewell	Recruiting
Pennington, New Jersey, United States, 08534
Contact: Site Public Contact 609-394-4130 clinicaltrials@capitalhealth.org
Principal Investigator: Arturo Loaiza-Bonilla
Sidney Kimmel Cancer Center Washington Township	Recruiting
Sewell, New Jersey, United States, 08080
Contact: Site Public Contact 215-600-9151 ONCTrialNow@jefferson.edu
Principal Investigator: Jennifer M. Johnson
Robert Wood Johnson University Hospital Somerset	Recruiting
Somerville, New Jersey, United States, 08876
Contact: Site Public Contact 908-685-2481 Siby.Varughese@rwjbh.org
Principal Investigator: Shridar Ganesan
United States, New Mexico
University of New Mexico Cancer Center	Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Site Public Contact 505-925-0348 HSC-ClinicalTrialInfo@salud.unm.edu
Principal Investigator: Bernard Tawfik
United States, New York
Montefiore Medical Center-Einstein Campus	Recruiting
Bronx, New York, United States, 10461
Contact: Site Public Contact 718-379-6866 eskwak@montefiore.org
Principal Investigator: Balazs Halmos
Montefiore Medical Center-Weiler Hospital	Recruiting
Bronx, New York, United States, 10461
Contact: Site Public Contact 718-379-6866 eskwak@montefiore.org
Principal Investigator: Balazs Halmos
Montefiore Medical Center - Moses Campus	Recruiting
Bronx, New York, United States, 10467
Contact: Site Public Contact 718-379-6866 eskwak@montefiore.org
Principal Investigator: Balazs Halmos
Roswell Park Cancer Institute	Recruiting
Buffalo, New York, United States, 14263
Contact: Site Public Contact 800-767-9355 askroswell@roswellpark.org
Principal Investigator: Ellis G. Levine
Memorial Sloan Kettering Commack	Recruiting
Commack, New York, United States, 11725
Contact: Site Public Contact 212-639-7592
Principal Investigator: Claire F. Friedman
Memorial Sloan Kettering Westchester	Recruiting
Harrison, New York, United States, 10604
Contact: Site Public Contact 212-639-7592
Principal Investigator: Claire F. Friedman
Mount Sinai Hospital	Recruiting
New York, New York, United States, 10029
Contact: Site Public Contact 212-824-7309 CCTO@mssm.edu
Principal Investigator: Deborah B. Doroshow
Memorial Sloan Kettering Cancer Center	Recruiting
New York, New York, United States, 10065
Contact: Site Public Contact 212-639-7592
Principal Investigator: Claire F. Friedman
State University of New York Upstate Medical University	Recruiting
Syracuse, New York, United States, 13210
Contact: Site Public Contact 315-464-5476
Principal Investigator: Mary J. Cunningham
United States, North Carolina
Southeastern Medical Oncology Center-Clinton	Recruiting
Clinton, North Carolina, United States, 28328
Contact: Site Public Contact 919-587-9084 jfields@cancersmoc.com
Principal Investigator: Samer S. Kasbari
Duke University Medical Center	Recruiting
Durham, North Carolina, United States, 27710
Contact: Site Public Contact 888-275-3853
Principal Investigator: John H. Strickler
Southeastern Medical Oncology Center-Goldsboro	Recruiting
Goldsboro, North Carolina, United States, 27534
Contact: Site Public Contact 919-587-9084 jfields@cancersmoc.com
Principal Investigator: Samer S. Kasbari
Southeastern Medical Oncology Center-Jacksonville	Recruiting
Jacksonville, North Carolina, United States, 28546
Contact: Site Public Contact 910-587-9084 jfields@cancersmoc.com
Principal Investigator: Samer S. Kasbari
Duke Women's Cancer Care Raleigh	Recruiting
Raleigh, North Carolina, United States, 27607
Contact: Site Public Contact 919-785-4878
Principal Investigator: John H. Strickler
United States, North Dakota
Sanford Bismarck Medical Center	Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Site Public Contact 701-323-5760 OncologyClinicalTrialsFargo@sanfordhealth.org
Principal Investigator: Daniel Almquist
Sanford Broadway Medical Center	Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact 701-323-5760 OncologyClinicalTrialsFargo@sanfordhealth.org
Principal Investigator: Daniel Almquist
Sanford Roger Maris Cancer Center	Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact 701-234-6161 OncologyClinicalTrialsFargo@sanfordhealth.org
Principal Investigator: Daniel Almquist
United States, Ohio
UH Seidman Cancer Center at UH Avon Health Center	Recruiting
Avon, Ohio, United States, 44011
Contact: Site Public Contact 800-641-2422
Principal Investigator: Alberto J. Montero
UHHS-Chagrin Highlands Medical Center	Recruiting
Beachwood, Ohio, United States, 44122
Contact: Site Public Contact 800-641-2422 CTUReferral@UHhospitals.org
Principal Investigator: Alberto J. Montero
Strecker Cancer Center-Belpre	Recruiting
Belpre, Ohio, United States, 45714
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Aultman Health Foundation	Recruiting
Canton, Ohio, United States, 44710
Contact: Site Public Contact 330-363-7274 ClinicalReserachDept@aultman.com
Principal Investigator: Adarsh Vennepureddy
Miami Valley Hospital South	Recruiting
Centerville, Ohio, United States, 45459
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org
Principal Investigator: Tarek M. Sabagh
Adena Regional Medical Center	Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Site Public Contact 877-779-7585 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Cincinnati Children's Hospital Medical Center	Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Site Public Contact 513-636-2799 cancer@cchmc.org
Principal Investigator: Joseph G. Pressey
Case Western Reserve University	Recruiting
Cleveland, Ohio, United States, 44106
Contact: Site Public Contact 800-641-2422 CTUReferral@UHhospitals.org
Principal Investigator: Alberto J. Montero
Cleveland Clinic Cancer Center/Fairview Hospital	Recruiting
Cleveland, Ohio, United States, 44111
Contact: Site Public Contact 866-223-8100 TaussigResearch@ccf.org
Principal Investigator: Emrullah Yilmaz
Cleveland Clinic Foundation	Recruiting
Cleveland, Ohio, United States, 44195
Contact: Site Public Contact 866-223-8100 TaussigResearch@ccf.org
Principal Investigator: Emrullah Yilmaz
Ohio State University Comprehensive Cancer Center	Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu
Principal Investigator: Floor Backes
Mount Carmel East Hospital	Recruiting
Columbus, Ohio, United States, 43213
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Columbus Oncology and Hematology Associates Inc	Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Riverside Methodist Hospital	Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Grant Medical Center	Recruiting
Columbus, Ohio, United States, 43215
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
The Mark H Zangmeister Center	Recruiting
Columbus, Ohio, United States, 43219
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Doctors Hospital	Recruiting
Columbus, Ohio, United States, 43228
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Dayton Blood and Cancer Center	Recruiting
Dayton, Ohio, United States, 45409
Contact: Site Public Contact 937-276-8320
Principal Investigator: Tarek M. Sabagh
Miami Valley Hospital	Recruiting
Dayton, Ohio, United States, 45409
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org
Principal Investigator: Tarek M. Sabagh
Miami Valley Hospital North	Recruiting
Dayton, Ohio, United States, 45415
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org
Principal Investigator: Tarek M. Sabagh
Delaware Health Center-Grady Cancer Center	Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Grady Memorial Hospital	Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Columbus Oncology and Hematology Associates	Recruiting
Dublin, Ohio, United States, 43016
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Dublin Methodist Hospital	Recruiting
Dublin, Ohio, United States, 43016
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Atrium Medical Center-Middletown Regional Hospital	Recruiting
Franklin, Ohio, United States, 45005-1066
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org
Principal Investigator: Tarek M. Sabagh
Miami Valley Cancer Care and Infusion	Recruiting
Greenville, Ohio, United States, 45331
Contact: Site Public Contact 937-569-7515
Principal Investigator: Tarek M. Sabagh
Zangmeister Center Grove City	Recruiting
Grove City, Ohio, United States, 43123
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Fairfield Medical Center	Recruiting
Lancaster, Ohio, United States, 43130
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
OhioHealth Mansfield Hospital	Recruiting
Mansfield, Ohio, United States, 44903
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
OhioHealth Marion General Hospital	Recruiting
Marion, Ohio, United States, 43302
Contact: Site Public Contact 614-788-3860 Jennifer.Sexton@ohiohealth.com
Principal Investigator: Aine E. Clements
Memorial Hospital	Recruiting
Marysville, Ohio, United States, 43040
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Hillcrest Hospital Cancer Center	Recruiting
Mayfield Heights, Ohio, United States, 44124
Contact: Site Public Contact 866-223-8100 TaussigResearch@ccf.org
Principal Investigator: Emrullah Yilmaz
UH Seidman Cancer Center at Lake Health Mentor Campus	Recruiting
Mentor, Ohio, United States, 44060
Contact: Site Public Contact 800-641-2422 CTUReferral@UHhospitals.org
Principal Investigator: Alberto J. Montero
UH Seidman Cancer Center at Southwest General Hospital	Active, not recruiting
Middleburg Heights, Ohio, United States, 44130
Knox Community Hospital	Recruiting
Mount Vernon, Ohio, United States, 43050
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Licking Memorial Hospital	Recruiting
Newark, Ohio, United States, 43055
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Mercy Health Perrysburg Cancer Center	Recruiting
Perrysburg, Ohio, United States, 43551
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Southern Ohio Medical Center	Recruiting
Portsmouth, Ohio, United States, 45662
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Springfield Regional Cancer Center	Recruiting
Springfield, Ohio, United States, 45504
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Springfield Regional Medical Center	Recruiting
Springfield, Ohio, United States, 45505
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Mercy Health - Saint Anne Hospital	Recruiting
Toledo, Ohio, United States, 43623
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Toledo Clinic Cancer Centers-Toledo	Recruiting
Toledo, Ohio, United States, 43623
Contact: Site Public Contact 800-444-3561
Principal Investigator: Rex B. Mowat
Upper Valley Medical Center	Recruiting
Troy, Ohio, United States, 45373
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org
Principal Investigator: Tarek M. Sabagh
Saint Ann's Hospital	Recruiting
Westerville, Ohio, United States, 43081
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
Genesis Healthcare System Cancer Care Center	Recruiting
Zanesville, Ohio, United States, 43701
Contact: Site Public Contact 614-488-2745 Jeffh@columbusccop.org
Principal Investigator: Timothy D. Moore
United States, Oklahoma
University of Oklahoma Health Sciences Center	Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact 405-271-8777 ou-clinical-trials@ouhsc.edu
Principal Investigator: Kathleen N. Moore
United States, Oregon
Providence Newberg Medical Center	Recruiting
Newberg, Oregon, United States, 97132
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org
Principal Investigator: Alison K. Conlin
Saint Alphonsus Medical Center-Ontario	Recruiting
Ontario, Oregon, United States, 97914
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org
Principal Investigator: John M. Schallenkamp
Providence Willamette Falls Medical Center	Recruiting
Oregon City, Oregon, United States, 97045
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org
Principal Investigator: Alison K. Conlin
Providence Portland Medical Center	Recruiting
Portland, Oregon, United States, 97213
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org
Principal Investigator: Alison K. Conlin
Providence Saint Vincent Medical Center	Recruiting
Portland, Oregon, United States, 97225
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org
Principal Investigator: Alison K. Conlin
Oregon Health and Science University	Recruiting
Portland, Oregon, United States, 97239
Contact: Site Public Contact 503-494-1080 trials@ohsu.edu
Principal Investigator: Christopher W. Ryan
United States, Pennsylvania
Lehigh Valley Hospital-Cedar Crest	Recruiting
Allentown, Pennsylvania, United States, 18103
Contact: Site Public Contact 610-402-9543 Morgan_M.Horton@lvhn.org
Principal Investigator: Tareq Al Baghdadi
UPMC Altoona	Recruiting
Altoona, Pennsylvania, United States, 16601
Contact: Site Public Contact ecog.rss@jimmy.harvard.edu
Principal Investigator: Adam M. Brufsky
Lehigh Valley Hospital - Muhlenberg	Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Site Public Contact 610-402-9543 Morgan_M.Horton@lvhn.org
Principal Investigator: Tareq Al Baghdadi
Bryn Mawr Hospital	Recruiting
Bryn Mawr, Pennsylvania, United States, 19010
Contact: Site Public Contact 484-476-2649 turzoe@mlhs.org
Principal Investigator: Paul B. Gilman
Pocono Medical Center	Recruiting
East Stroudsburg, Pennsylvania, United States, 18301
Contact: Site Public Contact 610-402-9543 Morgan_M.Horton@lvhn.org
Principal Investigator: Tareq Al Baghdadi
UPMC Hillman Cancer Center Erie	Recruiting
Erie, Pennsylvania, United States, 16505
Contact: Site Public Contact 412-389-5208 haneydl@upmc.edu
Principal Investigator: Adam M. Brufsky
UPMC Cancer Centers - Arnold Palmer Pavilion	Recruiting
Greensburg, Pennsylvania, United States, 15601
Contact: Site Public Contact 724-838-1900
Principal Investigator: Adam M. Brufsky
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion	Recruiting
Mechanicsburg, Pennsylvania, United States, 17050
Contact: Site Public Contact 412-389-5208 haneydl@upmc.edu
Principal Investigator: Adam M. Brufsky
Riddle Memorial Hospital	Recruiting
Media, Pennsylvania, United States, 19063
Contact: Site Public Contact 484-476-2649 turzoe@mlhs.org
Principal Investigator: Paul B. Gilman
UPMC Hillman Cancer Center - Monroeville	Recruiting
Monroeville, Pennsylvania, United States, 15146
Contact: Site Public Contact 412-389-5208 haneydl@upmc.edu
Principal Investigator: Adam M. Brufsky
Paoli Memorial Hospital	Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Site Public Contact 484-476-2649 turzoe@mlhs.org
Principal Investigator: Paul B. Gilman
Pennsylvania Hospital	Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Site Public Contact 800-789-7366
Principal Investigator: Mark S. Diamond
Thomas Jefferson University Hospital	Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Site Public Contact 215-600-9151 ONCTrialNow@jefferson.edu
Principal Investigator: Jennifer M. Johnson
University of Pittsburgh Cancer Institute (UPCI)	Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Site Public Contact 412-647-8073
Principal Investigator: Adam M. Brufsky
UPMC-Passavant Hospital	Recruiting
Pittsburgh, Pennsylvania, United States, 15237
Contact: Site Public Contact 412-367-6454
Principal Investigator: Adam M. Brufsky
Guthrie Medical Group PC-Robert Packer Hospital	Recruiting
Sayre, Pennsylvania, United States, 18840
Contact: Site Public Contact 800-836-0388
Principal Investigator: Joyson Poulose
Asplundh Cancer Pavilion	Recruiting
Willow Grove, Pennsylvania, United States, 19090
Contact: Site Public Contact 215-600-9151 ONCTrialNow@jefferson.edu
Principal Investigator: Jennifer M. Johnson
Lankenau Medical Center	Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Site Public Contact 484-476-2649 turzoe@mlhs.org
Principal Investigator: Paul B. Gilman
United States, Rhode Island
Women and Infants Hospital	Recruiting
Providence, Rhode Island, United States, 02905
Contact: Site Public Contact 401-274-1122
Principal Investigator: Paul A. DiSilvestro
United States, South Carolina
Prisma Health Cancer Institute - Spartanburg	Recruiting
Boiling Springs, South Carolina, United States, 29316
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
Prisma Health Richland Hospital	Recruiting
Columbia, South Carolina, United States, 29203
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
Prisma Health Cancer Institute - Easley	Recruiting
Easley, South Carolina, United States, 29640
Contact: Site Public Contact 864-522-2066 Kim.Williams3@prismahealth.org
Principal Investigator: Ki Y. Chung
BI-LO Charities Children's Cancer Center	Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
Prisma Health Cancer Institute - Butternut	Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
Prisma Health Cancer Institute - Faris	Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
Prisma Health Cancer Institute - Eastside	Recruiting
Greenville, South Carolina, United States, 29615
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
Prisma Health Cancer Institute - Greer	Recruiting
Greer, South Carolina, United States, 29650
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
Prisma Health Cancer Institute - Seneca	Recruiting
Seneca, South Carolina, United States, 29672
Contact: Site Public Contact 864-241-6251
Principal Investigator: Ki Y. Chung
United States, South Dakota
Sanford Cancer Center Oncology Clinic	Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Site Public Contact 605-312-3320 OncologyClinicTrialsSF@sanfordhealth.org
Principal Investigator: Daniel Almquist
Sanford USD Medical Center - Sioux Falls	Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Site Public Contact 605-312-3320 OncologyClinicalTrialsSF@SanfordHealth.org
Principal Investigator: Daniel Almquist
United States, Texas
Hendrick Medical Center	Recruiting
Abilene, Texas, United States, 79601
Contact: Site Public Contact 325-670-6340
Principal Investigator: Mustapha A. Khalife
M D Anderson Cancer Center	Recruiting
Houston, Texas, United States, 77030
Contact: Site Public Contact 877-632-6789 askmdanderson@mdanderson.org
Principal Investigator: Funda Meric-Bernstam
United States, Virginia
University of Virginia Cancer Center	Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Site Public Contact 434-243-6303 uvacancertrials@hscmail.mcc.virginia.edu
Principal Investigator: Matthew J. Reilley
Inova Schar Cancer Institute	Recruiting
Fairfax, Virginia, United States, 22031
Contact: Site Public Contact 703-720-5210 Stephanie.VanBebber@inova.org
Principal Investigator: Timothy L. Cannon
Inova Fairfax Hospital	Recruiting
Falls Church, Virginia, United States, 22042
Contact: Site Public Contact 703-208-6650 Stephanie.VanBebber@inova.org
Principal Investigator: Timothy L. Cannon
Virginia Cancer Institute	Recruiting
Richmond, Virginia, United States, 23229
Contact: Site Public Contact 804-287-3000 smoore@vacancer.com
Principal Investigator: Andrew Poklepovic
VCU Massey Cancer Center at Stony Point	Recruiting
Richmond, Virginia, United States, 23235
Contact: Site Public Contact ctoclinops@vcu.edu
Principal Investigator: Andrew Poklepovic
Virginia Commonwealth University/Massey Cancer Center	Recruiting
Richmond, Virginia, United States, 23298
Contact: Site Public Contact CTOclinops@vcu.edu
Principal Investigator: Andrew Poklepovic
VCU Community Memorial Health Center	Recruiting
South Hill, Virginia, United States, 23970
Contact: Site Public Contact nemer.elmouallem@vcuhealth.org
Principal Investigator: Andrew Poklepovic
United States, Washington
Swedish Cancer Institute-Edmonds	Recruiting
Edmonds, Washington, United States, 98026
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org
Principal Investigator: Alison K. Conlin
Swedish Cancer Institute-Issaquah	Recruiting
Issaquah, Washington, United States, 98029
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org
Principal Investigator: Alison K. Conlin
Valley Medical Center	Recruiting
Renton, Washington, United States, 98055
Contact: Site Public Contact 425-228-3440 research@valleymed.org
Principal Investigator: John A. Ellerton
Swedish Medical Center-First Hill	Recruiting
Seattle, Washington, United States, 98122
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org
Principal Investigator: Alison K. Conlin
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital	Recruiting
Yakima, Washington, United States, 98902
Contact: Site Public Contact 509-574-3535 Memorial-ClinicalTrials@yvmh.org
Principal Investigator: John A. Ellerton
United States, West Virginia
West Virginia University Charleston Division	Recruiting
Charleston, West Virginia, United States, 25304
Contact: Site Public Contact 304-388-9944
Principal Investigator: Ahmed A. Khalid
Edwards Comprehensive Cancer Center	Recruiting
Huntington, West Virginia, United States, 25701
Contact: Site Public Contact 304-399-6566 Christina.Cole@chhi.org
Principal Investigator: Maria R. Tria Tirona
West Virginia University Healthcare	Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Site Public Contact 304-293-7374 cancertrialsinfo@hsc.wvu.edu
Principal Investigator: Mohammed Almubarak
United States, Wisconsin
ThedaCare Regional Cancer Center	Recruiting
Appleton, Wisconsin, United States, 54911
Contact: Site Public Contact 920-364-3604 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
ThedaCare Regional Medical Center - Appleton	Recruiting
Appleton, Wisconsin, United States, 54911
Contact: Site Public Contact 920-364-3605 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
Duluth Clinic Ashland	Recruiting
Ashland, Wisconsin, United States, 54806
Contact: Site Public Contact 218-786-3308 CancerTrials@EssentiaHealth.org
Principal Investigator: Bret E. Friday
ThedaCare Cancer Care - Berlin	Recruiting
Berlin, Wisconsin, United States, 54923
Contact: Site Public Contact 920-364-3605 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
Aurora Cancer Care-Southern Lakes VLCC	Recruiting
Burlington, Wisconsin, United States, 53105
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Aurora Health Care Germantown Health Center	Recruiting
Germantown, Wisconsin, United States, 53022
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Aurora Cancer Care-Grafton	Recruiting
Grafton, Wisconsin, United States, 53024
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Saint Vincent Hospital Cancer Center Green Bay	Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: Site Public Contact 920-433-8889 ewd_research_admin@hshs.org
Principal Investigator: Brian L. Burnette
Saint Vincent Hospital Cancer Center at Saint Mary's	Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Site Public Contact 920-433-8889 ewd_research_admin@hshs.org
Principal Investigator: Brian L. Burnette
Aurora BayCare Medical Center	Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Mercyhealth Hospital and Cancer Center - Janesville	Recruiting
Janesville, Wisconsin, United States, 53548
Contact: Site Public Contact 608-756-6871 oncologyclinicaltrials@mhemail.org
Principal Investigator: Emily G. Robinson
Aurora Cancer Care-Kenosha South	Recruiting
Kenosha, Wisconsin, United States, 53142
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Gundersen Lutheran Medical Center	Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Site Public Contact 608-775-2385 cancerctr@gundersenhealth.org
Principal Investigator: Kurt Oettel
University of Wisconsin Carbone Cancer Center	Recruiting
Madison, Wisconsin, United States, 53792
Contact: Site Public Contact 800-622-8922 clinicaltrials@cancer.wisc.edu
Principal Investigator: Nataliya V. Uboha
Aurora Bay Area Medical Group-Marinette	Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Aurora Cancer Care-Milwaukee	Recruiting
Milwaukee, Wisconsin, United States, 53209
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Aurora Saint Luke's Medical Center	Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Aurora Sinai Medical Center	Recruiting
Milwaukee, Wisconsin, United States, 53233
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
ProHealth D N Greenwald Center	Recruiting
Mukwonago, Wisconsin, United States, 53149
Contact: Site Public Contact research.institute@phci.org
Principal Investigator: Timothy R. Wassenaar
ThedaCare Regional Medical Center - Neenah	Recruiting
Neenah, Wisconsin, United States, 54956
Contact: Site Public Contact 920-364-3605 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
ThedaCare Cancer Care - New London	Recruiting
New London, Wisconsin, United States, 54961
Contact: Site Public Contact 920-364-3605 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
ProHealth Oconomowoc Memorial Hospital	Recruiting
Oconomowoc, Wisconsin, United States, 53066
Contact: Site Public Contact 262-928-7878
Principal Investigator: Timothy R. Wassenaar
Saint Vincent Hospital Cancer Center at Oconto Falls	Recruiting
Oconto Falls, Wisconsin, United States, 54154
Contact: Site Public Contact 920-433-8889 ewd_research_admin@hshs.org
Principal Investigator: Brian L. Burnette
ThedaCare Cancer Care - Oshkosh	Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact 920-364-3605 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
Vince Lombardi Cancer Clinic - Oshkosh	Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Aurora Cancer Care-Racine	Recruiting
Racine, Wisconsin, United States, 53406
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
ThedaCare Cancer Care - Shawano	Recruiting
Shawano, Wisconsin, United States, 54166
Contact: Site Public Contact 920-364-3605 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
Saint Vincent Hospital Cancer Center at Sheboygan	Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Site Public Contact 920-433-8889 ewd_research_admin@hshs.org
Principal Investigator: Brian L. Burnette
Vince Lombardi Cancer Clinic-Sheboygan	Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Marshfield Medical Center-River Region at Stevens Point	Recruiting
Stevens Point, Wisconsin, United States, 54482
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org
Principal Investigator: Adedayo A. Onitilo
Saint Vincent Hospital Cancer Center at Sturgeon Bay	Recruiting
Sturgeon Bay, Wisconsin, United States, 54235-1495
Contact: Site Public Contact 920-433-8889 ewd_research_admin@hshs.org
Principal Investigator: Brian L. Burnette
Aurora Medical Center in Summit	Recruiting
Summit, Wisconsin, United States, 53066
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Vince Lombardi Cancer Clinic-Two Rivers	Recruiting
Two Rivers, Wisconsin, United States, 54241
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
UW Cancer Center at ProHealth Care	Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Site Public Contact 262-928-5539 Chanda.miller@phci.org
Principal Investigator: Timothy R. Wassenaar
ThedaCare Cancer Care - Waupaca	Recruiting
Waupaca, Wisconsin, United States, 54981
Contact: Site Public Contact 920-364-3605 ResearchDept@thedacare.org
Principal Investigator: Matthias Weiss
Aurora Cancer Care-Milwaukee West	Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Aurora West Allis Medical Center	Recruiting
West Allis, Wisconsin, United States, 53227
Contact: Site Public Contact 414-302-2304 ncorp@aurora.org
Principal Investigator: Antony Ruggeri
Marshfield Medical Center - Weston	Recruiting
Weston, Wisconsin, United States, 54476
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org
Principal Investigator: Adedayo A. Onitilo
Puerto Rico
Doctors Cancer Center	Recruiting
Manati, Puerto Rico, 00674
Contact: Site Public Contact 787-621-4397
Principal Investigator: Luis J. Santos Reyes
Centro Comprensivo de Cancer de UPR	Recruiting
San Juan, Puerto Rico, 00927
Contact: Site Public Contact ecog.rss@jimmy.harvard.edu
Principal Investigator: Luis J. Santos Reyes
PROncology	Recruiting
San Juan, Puerto Rico, 00927
Contact: Site Public Contact 787-919-7919 info@PRoncology.com
Principal Investigator: Luis J. Santos Reyes

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators

Layout table for investigator information

Principal Investigator:	James M Ford	ECOG-ACRIN Cancer Research Group

More Information

Layout table for additonal information

Responsible Party:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT05564377
Other Study ID Numbers:	NCI-2022-06842 NCI-2022-06842 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) EAY191 ( Other Identifier: ECOG-ACRIN Cancer Research Group ) EAY191 ( Other Identifier: CTEP ) U10CA180820 ( U.S. NIH Grant/Contract )
First Posted:	October 3, 2022 Key Record Dates
Last Update Posted:	May 9, 2024
Last Verified:	March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Yes
Plan Description:	NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
URL:	https://grants.nih.gov/policy/sharing.htm

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No
Product Manufactured in and Exported from the U.S.:	No

Additional relevant MeSH terms:

Layout table for MeSH terms

Carcinoma Breast Neoplasms Neoplasms Endometrial Neoplasms Genital Neoplasms, Female Recurrence Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms by Site Breast Diseases Skin Diseases Disease Attributes Pathologic Processes Uterine Neoplasms Urogenital Neoplasms	Uterine Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Diseases Leucovorin Paclitaxel Oxaliplatin Fluorouracil Albumin-Bound Paclitaxel Fulvestrant Olaparib Palbociclib Panitumumab

To Top